ATARA BIOTHERAPEUTICS INC. overview

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the second quarter 2022, an update to its corporate strategy, recent business highlights, and key upcoming catalysts. “We are excited about the transformative potential of ATA188 in MS and are pleased that as a result of our significant and...

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Atara Biotherapeutics, Inc. (“Atara” or the “Company”) (NASDAQ: ATRA) on behalf of Atara stockholders. Our investigation concerns whether Atara has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On November 4, 2021, Atara issued a press release touting its T cell immunotherapy...

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Atara Biotherapeutics, Inc. (“Atara” or the “Company”) (NASDAQ: ATRA) on behalf of Atara stockholders. Our investigation concerns whether Atara has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On November 4, 2021, Atara issued a press release touting its T cell immunotherapy...

ATRA INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Atara Biotherapeutics, Inc. PR Newswire NEW YORK, Aug. 4, 2022 NEW YORK , Aug. 4, 2022 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ: ATRA) concerning possible violations of federal securities laws. On November 4, 2021 ,...

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of 82,756 restricted stock units of Atara’s common stock to four newly hired employees and stock options to purchase an aggregate of 98,701 shares of Atara’s common stock to two such newly hired employees. These awards were approved by the...

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will present at the Canaccord Genuity 42nd Annual Growth Conference on Thursday, August 11, 2022 at 9:00 a.m. PDT / 12:00 p.m. EDT. A live webcast of the presentation will be available by...

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release second quarter 2022 financial results after market close on Monday, August 8, 2022. Following the release, the Company will host a live conference call and webcast at 4:30 p.m. EDT to discuss the Company’s financial...

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. (“Atara” or “the Company”) (NASDAQ: ATRA ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Atara issued a press release on July 12, 2022, updating the market on its preliminary...